Key Considerations for Reshoring U.S. Drug Manufacturing
To help businesses, investors, and deal professionals better understand the evolving M&A market, Robert Connolly – a partner in and leader of LP’s Corporate Practice Group – shares a series of conversations with M&A experts....more
As companies continue to battle supply chain challenges reshoring continues to be a trend discussed in all sorts of industries. When reshoring is mentioned, it is normally in the context of reshoring to the country of the...more
In late 2012, we created the Manufacturing Law Blog with the goal of providing our manufacturing clients with a holistic approach to the unique issues they face in their global operations. ...more
This Diagnosing Health Care episode dives into the key business operations and legal considerations for reshoring active pharmaceutical ingredient (or “API”) and finished drug product manufacturing to the United States. The...more
There has been a lot of talk about “reshoring” in the wake of COVID-19. Reshoring can take many forms. It usually refers to a company moving manufacturing facilities or services back to the United States. Other times, it...more
One of the less-discussed but significant federal relief programs that has been enacted over the past several months is the DFC-DPA Loan Program, which is being administered through the United States International Development...more